This Program Project will require an integrated suite of tools to support the proposed information-intensive studiesin a cost effective and efficient manner. The spectrum of needs, from those of a basic scientist to those of anoutcomes-based clinical investigators requires a robust architecture of software, hardware and informationtechnology professionals to develop and maintain these tools. The cost of equipment, the rapid pace oftechnology development and the specialized expertise (e.g. clinical trials support, information management, datamanagers, quality control tools, tissue banking informatics and honest brokers systems, HIPAA compliancespecialists, bioinformatics analyst, network/storage specialists, etc...) required to properly manage the informaticsneeds of the Program Project are not possible without high quality and efficient Cancer Informatics Services(CIS). It is therefore critical that this resource be well supported and integrated into the research and clinicalmissions of this PPG. The CIS team is a lead developer for the Cancer Biomedical Informatics Grid (caBIG) andall of the data sharing services offered will communicate with NCI data grid. The CIS proposed for this PPG iscomposed of the following integrated services:1) Clinical Trials Management Application - this tool manages all of the clinical trials data and formats it foranalysis2) Tissue Banking Information Systems - the CIS core supplies the Core with the tools to support pathologicannotation and inventory control of the biospecimen (tissue, blood, serum and body fluids) requests of theprogram project researchers. These software tools developed by CIS assist in providing a secure environment forthe collaborative honest broker activities of the Core.3) Registry Research Information Services - supporting all of the clinical and outcomes annotation of patients inclinical trials and who contribute their cancer tissues to the tissue bank4) Organ Specific Databases-a data mining tool for organ site specific programs that facilitates HIPAAcompliant and de-identified access to patient tumor stage, grade, etc, as well as study cohort availability5) Data Sharing, Storage, Archival and Network Services - robust network and storage solutions for clinicaltrials, tissue banking, data sharing and data archiving with active data maintenance and back up will be caBIGcompliant.Innovative tumor immunology discovery relies on robust research information services to more effectively supportthe translation of innovation from the laboratory to the bedside and to utilize critical clinical and outcomes data toguide discovery at the bench and vice versa. This will be the key focus of the CIS in support of this PPG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA109688-01A2
Application #
7116666
Study Section
Special Emphasis Panel (ZCA1-GRB-2 (J))
Project Start
2006-04-01
Project End
2011-03-31
Budget Start
2006-09-30
Budget End
2007-07-31
Support Year
1
Fiscal Year
2006
Total Cost
$66,505
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Spitler, Lynn E; Cao, Huynh; Piironen, Timo et al. (2017) Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated With GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma. Am J Clin Oncol 40:207-213
Macatangay, Bernard J C; Riddler, Sharon A; Wheeler, Nicole D et al. (2016) Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. J Infect Dis 213:1400-9
Szczepanski, Miroslaw J; Luczak, Michal; Olszewska, Ewa et al. (2015) Molecular signaling of the HMGB1/RAGE axis contributes to cholesteatoma pathogenesis. J Mol Med (Berl) 93:305-14
Whiteside, Theresa L (2015) Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV. Cancer Microenviron 8:201-7
Schuler, P J; Saze, Z; Hong, C-S et al. (2014) Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. Clin Exp Immunol 177:531-43
Schuler, Patrick J; Harasymczuk, Malgorzata; Visus, Carmen et al. (2014) Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 20:2433-44
Whiteside, Theresa L (2014) Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 63:67-72
Jie, H-B; Gildener-Leapman, N; Li, J et al. (2013) Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 109:2629-35
Szczepanski, Miroslaw J; Whiteside, Theresa L (2013) Elevated PRAME expression: what does this mean for treatment of head and neck squamous cell carcinoma? Biomark Med 7:575-8
Chen, L; Taylor, J L; Sabins, N C et al. (2013) Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells. Cancer Gene Ther 20:469-77

Showing the most recent 10 out of 110 publications